|
|
 | | | |
- close
- close
- close
- close
Smith & Nephew SNATS (SNN) |
Suggest other news sources for this topic
WIKI ANALYSIS
Smith & Nephew (NYSE:SNN) is a global medical devices business engaged in orthopaedic reconstruction, orthopaedic trauma and clinical therapies, endoscopy and advanced wound management having revenue of over $2.7 billion in 2006. It is an English public limited company with its shares listed on the official list of the UK Listing Authority and it is traded on the London Stock Exchange and on the New York Stock Exchange in the form of ADSs. [1] Smith & Nephew primarily competes with Stryker (SYK), JOHNSON & JOHNSON (JNJ)’s DePuy subsidiary, Zimmer Holdings (ZMH) , and Biomet (BMET).
Business Overview
Smith & Nephew operates in three main market segments: Orthopaedic Reconstruction, Trauma and Clinical Therapies, Endoscopy, and Advanced Wound Management
- Orthopaedic Reconstruction: Reconstruction implants include hip, knee and shoulder joints as well as ancillary products such as bone cement and mixing systems used in cemented reconstruction joint surgery. The reconstruction business is managed worldwide from Memphis, Tennessee, which also houses its main manufacturing facility. [2]
- Trauma and Clinical Therapies: Trauma products consist of internal and external fixation devices and orthobiological materials used in the stabilization of severe fractures and deformity correction procedures and clinical therapies consist of products used in the areas of bone growth stimulation and joint fluid therapy.[3]
- Endoscopy: Smith & Nephew’s endoscopy business, headquartered in Andover, Massachusetts, develops and commercializes endoscopic techniques, educational programs and value-added services for surgeons to treat and repair soft tissue. The business focuses principally on arthroscopy, minimally invasive surgery of the knee, shoulder and hip joints.[4]
- Advanced Wound Management: Smith & Nephew’s advanced wound management business is headquartered in Hull, England and offers a range of products from initial wound bed preparation through full wound closure. These products are targeted particularly at chronic wounds connected with the older population, such as pressure sores and venous leg ulcers, burns and complex surgical wounds.[5]
References
- ↑ SNN 2006 20f, Pg 1
- ↑ SNN 2006 20f, Pg 4
- ↑ SNN 2006 20f, Pg 7
- ↑ SNN 2006 20f, Pg 9
- ↑ SNN 2006 20f, Pg 11
| |||||||
